Recombinant E. coli converts 3-cyanopyridine to niacin with a yield of 98.6%, highlighting its potential as a biocatalyst.
Niacin is a compound with a wide range of applications in pharmaceuticals, healthcare, food nutrition, animal breeding, cosmetics, etc. A recombinant Escherichia coli carrying the afnitA nitrilase gene was created to transform 3-cyanopyridine into niacin in this work. After analyzing the viscosity, surface tension, and Kamlet-Taft (K-T) parameters (π*, α, and β values) of certain deep eutectic solvents (DESs), Betaine:Acetic Acid (Betaine:AA) (1:2, mol/mol) was chosen as the bioreaction medium. Using response surface methodology (RSM), systematic biocatalytic optimization was performed. The optimum medium pH, cell loading, temperature, and DES (Betaine:AA) (1:2, mol/mol) dose were determined to be 7.75, 195 g/L, 44.24 °C, and 18.04 wt%. Under the optimized conditions, whole-cell catalysis facilitated the conversion of 3-cyanopyridine to niacin, achieving a high yield of 98.6% within 40 min. These results demonstrated that recombinant E. coli carrying the afnitA nitrilase gene may have practical value as a biocatalyst for the production of niacin, with promising prospects for future applications.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: